» Articles » PMID: 17924548

Sickle Cell Bone Disease: Response to Vitamin D and Calcium

Overview
Journal Am J Hematol
Specialty Hematology
Date 2007 Oct 11
PMID 17924548
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Bone disease with osteoporosis and osteomalacia are common in sickle cell disease (SCD). Some patients have vitamin D deficiency and low bone mineral density (BMD). The role of vitamin D and calcium supplementation to restore bone health in SCD has not been well studied. In 14 adults with SCD, we measured 25(OH)D (25-hydroxyvitamin D) and BMD at the femoral neck, lumbar spine, and distal third of the ulna plus radius, along with markers of bone resorption (CTx; C-terminal component of pro-collagen type I) and bone formation (osteocalcin) before and after 12 months of vitamin D(2) and calcium carbonate treatment. Pretreatment, all patients were vitamin D deficient with a mean 25(OH)D level of 11.6 [corrected] +/- 4 [corrected] ng/ml, had low BMD at the lumbar spine (L-spine), 0.87 +/- 0.11 g/cm(2) (mean Z-score of -2.6 3 +/- 0.71 SD and T score of -2.31 +/- 0.75 SD), femoral neck, 0.8 +/- 0.18 g/cm(2) (mean Z-score -1.36 +/- 0.84, T-score -1.14 +/- 0.75), and the distal radius and ulna, 0.6 +/- 0.17 g/cm(2) (mean Z-score -1.18 +/- 0.79, T-score -1.01 +/- 0.74) and had elevated CTx (0.87 +/- 0.5 ng/ml) and osteocalcin levels (12.3 +/- 3.7 ng/mul). After treatment, all patients corrected their 25(OH)D level (34.6 [corrected] +/- 11 [corrected] ng/ml) (P < 0.001) with a 3.6% +/- 3.9% increase in BMD at the L-spine (P = 0.009), 4.6% +/- 8.5% increase at the femoral neck (P = 0.05) and 6.5% +/- 12.6% increase at the distal radius plus ulna (P = 0.09). CTx, osteocalcin, and PTH(i) levels were unchanged. Treatment of adult SCD with vitamin D and calcium can restore 25(OH)D levels to normal and improve BMD, but, markers of bone resorption remained unchanged. Screening for vitamin D deficiency and BMD in SCD patients seems warranted.

Citing Articles

Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice.

Tripathi A, Dabeer S, Song J, Vikulina T, Roser-Page S, Alvarez J Cell Death Dis. 2024; 15(12):907.

PMID: 39695103 PMC: 11655664. DOI: 10.1038/s41419-024-07296-z.


Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.

Di Paola A, Marrapodi M, Di Martino M, Giliberti G, Di Feo G, Rana D Int J Mol Sci. 2024; 25(5).

PMID: 38474150 PMC: 10932404. DOI: 10.3390/ijms25052902.


Evaluation of Mandibular Bone Microstructure in CT Scans of People with Sickle Cell Disease.

Almeida V, Soares M, Leite-Ribeiro P, Rubira-Bullen I, Lins-Kusterer L, Sarmento V Eur J Dent. 2023; 18(1):356-359.

PMID: 37729929 PMC: 10959614. DOI: 10.1055/s-0043-1771200.


Management of the Sickle Cell Trait: An Opinion by Expert Panel Members.

Pinto V, De Franceschi L, Gianesin B, Gigante A, Graziadei G, Lombardini L J Clin Med. 2023; 12(10).

PMID: 37240547 PMC: 10219090. DOI: 10.3390/jcm12103441.


Primary Hyperparathyroidism in Homozygous Sickle Cell Patients: A Hemolysis-Mediated Hypocalciuric Hypercalcemia Phenotype?.

Khan E, Cheddani L, Saint-Jacques C, Vargas-Poussou R, Frochot V, Chieze R J Clin Med. 2021; 10(21).

PMID: 34768698 PMC: 8584729. DOI: 10.3390/jcm10215179.